PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
60.05%
R&D growth while RVPH reduces spending. John Neff would investigate strategic advantage.
231.77%
G&A growth above 1.5x RVPH's 51.19%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.69%
Operating expenses growth above 1.5x RVPH's 4.03%. Michael Burry would check for inefficiency.
-100.00%
Total costs reduction while RVPH shows 4.03% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
D&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
-127.89%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-121.69%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-17.94%
Other expenses reduction while RVPH shows 270.17% growth. Joel Greenblatt would examine advantage.
-139.60%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-139.60%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-131.82%
EPS decline while RVPH shows 11.32% growth. Joel Greenblatt would examine position.
-131.82%
Diluted EPS decline while RVPH shows 11.32% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.